nach oben

Erschienen in:

01.12.2013 | Short Communication

p53 immunohistochemical expression and patient prognosis in esophageal squamous cell carcinoma

verfasst von: Asuka Murata, Yoshifumi Baba, Masayuki Watanabe, Hironobu Shigaki, Keisuke Miyake, Ryuichi Karashima, Yu Imamura, Satoshi Ida, Takatsugu Ishimoto, Shiro Iwagami, Yasuo Sakamoto, Yuji Miyamoto, Naoya Yoshida, Hideo Baba

Erschienen in: Medical Oncology | Ausgabe 4/2013

Einloggen, um Zugang zu erhalten

Abstract

It is generally accepted that overexpression of p53 protein is associated with poor prognosis in gastric, lung, and other types of cancer. However, the prognostic significance of p53 aberrations in esophageal cancer remains unclear. This is the largest study (n = 266) examining clinical and prognostic features of p53 immunohistochemical expression in esophageal squamous cell carcinoma. In 139 (52 %) esophageal tumors, nuclear immunoreactivity for p53 protein was detected. p53 aberrant expression was not associated with sex, age, preoperative treatment, TNM stage, or histological grade. Furthermore, p53 expression did not correlate with disease-free survival (P = 0.73) or overall survival (P = 0.62). In addition, no significant modification effect by any of the covariates in the survival analysis was observed (all P > 0.15). In conclusion, our large-scale study demonstrates that p53 expression has no impact on the prognosis of esophageal squamous cell carcinoma.

Enzinger PC, Mayer RJ. Esophageal cancer. N Engl J Med. 2003;349:2241–52.CrossRefPubMed

Rizk NP, Ishwaran H, Rice TW, Chen LQ, Schipper PH, Kesler KA, et al. Optimum lymphadenectomy for esophageal cancer. Ann Surg. 2010;251:46–50.CrossRefPubMed

Allum WH, Stenning SP, Bancewicz J, Clark PI, Langley RE. Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer. J Clin Oncol. 2009;27:5062–7.CrossRefPubMed

Gertler R, Stein HJ, Langer R, Nettelmann M, Schuster T, Hoefler H, et al. Long-term outcome of 2920 patients with cancers of the esophagus and esophagogastric junction: evaluation of the New Union Internationale Contre le Cancer/American Joint Cancer Committee staging system. Ann Surg. 2011;253:689–98.CrossRefPubMed

Hong L, Han Y, Zhang H, Li M, Gong T, Sun L, et al. The prognostic and chemotherapeutic value of miR-296 in esophageal squamous cell carcinoma. Ann Surg. 2010;251:1056–63.CrossRefPubMed

Hildebrandt MA, Yang H, Hung MC, Izzo JG, Huang M, Lin J, et al. Genetic variations in the PI3 K/PTEN/AKT/mTOR pathway are associated with clinical outcomes in esophageal cancer patients treated with chemoradiotherapy. J Clin Oncol. 2009;27:857–71.CrossRefPubMedCentralPubMed

Levine AJ, Oren M. The first 30 years of p53: growing ever more complex. Nat Rev Cancer. 2009;9:749–58.CrossRefPubMedCentralPubMed

Vousden KH, Prives C. Blinded by the light: the growing complexity of p53. Cell. 2009;137:413–31.CrossRefPubMed

Greenblatt MS, Bennett WP, Hollstein M, Harris CC. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res. 1994;54:4855–78.PubMed

10.

Hall PA, Lane DP. p53 in tumour pathology: can we trust immunohistochemistry?–Revisited! J Pathol. 1994;172:1–4.CrossRefPubMed

11.

Bennett WP, Hollstein MC, Metcalf RA, Welsh JA, He A, Zhu SM, et al. p53 mutation and protein accumulation during multistage human esophageal carcinogenesis. Cancer Res. 1992;52:6092–7.PubMed

12.

Qiao GB, Han CL, Jiang RC, Sun CS, Wang Y, Wang YJ. Overexpression of P53 and its risk factors in esophageal cancer in urban areas of Xi’an. World J Gastroenterol. 1998;4:57–60.PubMed

13.

Wynford-Thomas D. P53 in tumour pathology: can we trust immunocytochemistry? J Pathol. 1992;166:329–30.CrossRefPubMed

14.

Okumura H, Kita Y, Yokomakura N, Uchikado Y, Setoyama T, Sakurai H, et al. Nuclear expression of 14-3-3 sigma is related to prognosis in patients with esophageal squamous cell carcinoma. Anticancer Res. 2010;30:5175–9.PubMed

15.

Kanamoto A, Kato H, Tachimori Y, Watanabe H, Nakanishi Y, Kondo H, et al. No prognostic significance of p53 expression in esophageal squamous cell carcinoma. J Surg Oncol. 1999;72:94–8.CrossRefPubMed

16.

Sarbia M, Borchard F, Gabbert HE, Porschen R, Horstmann O, Willers R. P53 protein expression and prognosis in squamous cell carcinoma of the esophagus. Cancer. 1994;74:2218–23.CrossRefPubMed

17.

Baba Y, Watanabe M, Shigaki H, Iwagami S, Ishimoto T, Iwatsuki M, et al. Negative lymph-node count is associated with survival in patients with resected esophageal squamous cell carcinoma. Surgery. 2013;153:234–41.CrossRefPubMed

18.

Ozawa S, Baba S, Fujishiro M, Matsubara H, Numasaki H, Oyama T, et al. Comprehensive Registry of Esophageal Cancer in Japan. Esophagus. 2012;9:75–98.CrossRef

19.

McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst. 2005;97:1180–4.CrossRefPubMed

20.

Lam KY, Loke SL, Chen WZ, Cheung KN, Ma L. Expression of p53 in oesophageal squamous cell carcinoma in Hong Kong Chinese. Eur J Surg Oncol. 1995;21:242–7.CrossRefPubMed

21.

Yokoyama A, Tanaka Y, Yokoyama T, Mizukami T, Matsui T, Maruyama K, et al. p53 protein accumulation, iodine-unstained lesions, and alcohol dehydrogenase-1B and aldehyde dehydrogenase-2 genotypes in Japanese alcoholic men with esophageal dysplasia. Cancer Lett. 2011;308:112–7.CrossRefPubMed

22.

Goan YG, Chang HC, Hsu HK, Chou YP, Cheng JT. Risk of p53 gene mutation in esophageal squamous cell carcinoma and habit of betel quid chewing in Taiwanese. Cancer Sci. 2005;96:758–65.CrossRefPubMed

23.

Kato H, Yoshikawa M, Miyazaki T, Nakajima M, Fukai Y, Tajima K, et al. Expression of p53 protein related to smoking and alcoholic beverage drinking habits in patients with esophageal cancers. Cancer Lett. 2001;167:65–72.CrossRefPubMed

24.

Mizobuchi S, Furihata M, Sonobe H, Ohtsuki Y, Ishikawa T, Murakami H, et al. Association between p53 immunostaining and cigarette smoking in squamous cell carcinoma of the esophagus. Jpn J Clin Oncol. 2000;30:423–8.CrossRefPubMed

25.

Taghavi N, Biramijamal F, Sotoudeh M, Moaven O, Khademi H, Abbaszadegan MR, et al. Association of p53/p21 expression with cigarette smoking and prognosis in esophageal squamous cell carcinoma patients. World J Gastroenterol. 2010;16:4958–67.CrossRefPubMedCentralPubMed

26.

Tanaka F, Yamamoto K, Suzuki S, Inoue H, Tsurumaru M, Kajiyama Y, et al. Strong interaction between the effects of alcohol consumption and smoking on oesophageal squamous cell carcinoma among individuals with ADH1B and/or ALDH2 risk alleles. Gut. 2010;59:1457–64.CrossRefPubMed

27.

Steevens J, Schouten LJ, Goldbohm RA, van den Brandt PA. Alcohol consumption, cigarette smoking and risk of subtypes of oesophageal and gastric cancer: a prospective cohort study. Gut. 2010;59:39–48.CrossRefPubMed

28.

Morita M, Kumashiro R, Kubo N, Nakashima Y, Yoshida R, Yoshinaga K, et al. Alcohol drinking, cigarette smoking, and the development of squamous cell carcinoma of the esophagus: epidemiology, clinical findings, and prevention. Int J Clin Oncol. 2010;15:126–34.CrossRefPubMed

29.

Yokoyama A, Kumagai Y, Yokoyama T, Omori T, Kato H, Igaki H, et al. Health risk appraisal models for mass screening for esophageal and pharyngeal cancer: an endoscopic follow-up study of cancer-free Japanese men. Cancer Epidemiol Biomarkers Prev. 2009;18:651–5.CrossRefPubMed

30.

Yokoyama A, Omori T, Yokoyama T, Sato Y, Mizukami T, Matsushita S, et al. Risk of squamous cell carcinoma of the upper aerodigestive tract in cancer-free alcoholic Japanese men: an endoscopic follow-up study. Cancer Epidemiol Biomarkers Prev. 2006;15:2209–15.CrossRefPubMed

31.

Wang LD, Zhou Q, Hong JY, Qiu SL, Yang CS. p53 protein accumulation and gene mutations in multifocal esophageal precancerous lesions from symptom free subjects in a high incidence area for esophageal carcinoma in Henan China. Cancer. 1996;77:1244–9.CrossRefPubMed

32.

Shigaki H, Baba Y, Watanabe M, Iwagami S, Miyake K, Ishimoto T, et al. LINE-1 hypomethylation in noncancerous esophageal mucosae is associated with smoking history. Ann Surg Oncol. 2012;19:4238–43.CrossRefPubMed

33.

Oka D, Yamashita S, Tomioka T, Nakanishi Y, Kato H, Kaminishi M, et al. The presence of aberrant DNA methylation in noncancerous esophageal mucosae in association with smoking history: a target for risk diagnosis and prevention of esophageal cancers. Cancer. 2009;115:3412–26.CrossRefPubMed

34.

Lam KY, Law S, Tin L, Tung PH, Wong J. The clinicopathological significance of p21 and p53 expression in esophageal squamous cell carcinoma: an analysis of 153 patients. Am J Gastroenterol. 1999;94:2060–8.CrossRefPubMed

35.

Yen CC, Tsao YP, Chen PC, Wu YC, Liu JH, Pan CC, et al. PML protein as a prognostic molecular marker for patients with esophageal squamous cell carcinomas receiving primary surgery. J Surg Oncol. 2011;103:761–7.CrossRefPubMed

36.

Sarbia M, Porschen R, Borchard F, Horstmann O, Willers R, Gabbert HE. p53 protein expression and prognosis in squamous cell carcinoma of the esophagus. Cancer. 1994;74:2218–23.CrossRefPubMed

37.

Shimaya K, Shiozaki H, Inoue M, Tahara H, Monden T, Shimano T, et al. Significance of p53 expression as a prognostic factor in oesophageal squamous cell carcinoma. Virchows Arch A Pathol Anat Histopathol. 1993;422:271–6.CrossRefPubMed

38.

Wang LD, Shi ST, Zhou Q, Goldstein S, Hong JY, Shao P, et al. Changes in p53 and cyclin D1 protein levels and cell proliferation in different stages of human esophageal and gastric-cardia carcinogenesis. Int J Cancer. 1994;59:514–9.CrossRefPubMed

39.

Sarbia M, Ott N, Puhringer-Oppermann F, Brucher BL. The predictive value of molecular markers (p53, EGFR, ATM, CHK2) in multimodally treated squamous cell carcinoma of the oesophagus. Br J Cancer. 2007;97:1404–8.CrossRefPubMedCentralPubMed

40.

Okamoto H, Fujishima F, Nakamura Y, Zuguchi M, Ozawa Y, Takahashi Y, et al. Significance of CD133 expression in esophageal squamous cell carcinoma. World J Surg Oncol. 2013;11:51.CrossRefPubMedCentralPubMed

41.

Ikeguchi M, Saito H, Katano K, Tsujitani S, Maeta M, Kaibara N. Clinicopathologic significance of the expression of mutated p53 protein and the proliferative activity of cancer cells in patients with esophageal squamous cell carcinoma. J Am Coll Surg. 1997;185:398–403.CrossRefPubMed

42.

Chanvitan A, Nekarda H, Casson AG. Prognostic value of DNA index, S-phase fraction and p53 protein accumulation after surgical resection of esophageal squamous-cell carcinomas in Thailand. Int J Cancer. 1995;63:381–6.CrossRefPubMed

43.

Furihata M, Ohtsuki Y, Ogoshi S, Takahashi A, Tamiya T, Ogata T. Prognostic significance of human papillomavirus genomes (type-16, -18) and aberrant expression of p53 protein in human esophageal cancer. Int J Cancer. 1993;54:226–30.CrossRefPubMed

44.

Nakamura T, Ide H, Eguchi R, Hayashi K, Hanyu F, Nagasako K, et al. Expression of p53 protein related to human papillomavirus and DNA ploidy in superficial esophageal carcinoma. Surg Today. 1995;25:591–7.CrossRefPubMed

45.

Casson AG, Tammemagi M, Eskandarian S, Redston M, McLaughlin J, Ozcelik H. p53 alterations in oesophageal cancer: association with clinicopathological features, risk factors, and survival. Mol Pathol. 1998;51:71–9.CrossRefPubMedCentralPubMed

46.

Monges GM, Seitz JF, Giovannini MF, Gouvernet JM, Torrente MA, Hassoun JA. Prognostic value of p53 protein expression in squamous cell carcinoma of the esophagus. Cancer Detect Prev. 1996;20:63–7.PubMed

47.

Yamamoto Y, Yamai H, Seike J, Yoshida T, Takechi H, Furukita Y, et al. Prognosis of Esophageal Squamous Cell Carcinoma in Patients Positive for Human Epidermal Growth Factor Receptor Family Can Be Improved by Initial Chemotherapy with Docetaxel, Fluorouracil, and Cisplatin. Ann Surg Oncol. 2011;19:757–65.CrossRefPubMed

48.

Rosa AR, Schirmer CC, Gurski RR, Meurer L, Edelweiss MI, Kruel CD. Prognostic value of p53 protein expression and vascular endothelial growth factor expression in resected squamous cell carcinoma of the esophagus. Dis Esophagus. 2003;16:112–8.CrossRefPubMed

49.

Coggi G, Bosari S, Roncalli M, Graziani D, Bossi P, Viale G, et al. p53 protein accumulation and p53 gene mutation in esophageal carcinoma. Cancer. 1997;79:425–32.CrossRefPubMed

50.

Goukon Y, Sasano H, Nishihira T, Nagura H, Mori S. p53 overexpression in human esophageal carcinoma: a correlation with tumor DNA ploidy and two parameter flow cytometric study. Anticancer Res. 1994;14:1305–12.PubMed

51.

Inada S, Koto T, Futami K, Arima S, Iwashita A. Evaluation of malignancy and the prognosis of esophageal cancer based on an immunohistochemical study (p53, E-cadherin, epidermal growth factor receptor). Surg Today. 1999;29:493–503.CrossRefPubMed

52.

Hsia JY, Chen CY, Hsu CP, Shai SE, Yang SS, Chuang CY, et al. Expression of apoptosis-regulating proteins p53, Bcl-2, and Bax in primary resected esophageal squamous cell carcinoma. Neoplasma. 2001;48:483–8.PubMed

53.

Uchino S, Saito T, Inomata M, Osawa N, Chikuba K, Etoh K, et al. Prognostic significance of the p53 mutation in esophageal cancer. Jpn J Clin Oncol. 1996;26:287–92.CrossRefPubMed

54.

Vijeyasingam R, Darnton SJ, Jenner K, Allen CA, Billingham C, Matthews HR. Expression of p53 protein in oesophageal carcinoma: clinicopathological correlation and prognostic significance. Br J Surg. 1994;81:1623–6.CrossRefPubMed

55.

Chyczewski L, Kozlowski M, Niklinski J, Szyszko J, Laudanski J, Niklinska W. p53 protein expression in resected invasive esophageal cancer. Neoplasma. 1999;46:150–5.PubMed

56.

Patel DD, Bhatavdekar JM, Chikhlikar PR, Patel YV, Shah NG, Ghosh N, et al. Clinical significance of p53, nm23, and bcl-2 in T3-4N1M0 oesophageal carcinoma: an immunohistochemical approach. J Surg Oncol. 1997;65:111–6.CrossRefPubMed

57.

Pomp J, Davelaar J, Blom J, van Krimpen C, Zwinderman A, Quint W, et al. Radiotherapy for oesophagus carcinoma: the impact of p53 on treatment outcome. Radiother Oncol. 1998;46:179–84.CrossRefPubMed

Titel: p53 immunohistochemical expression and patient prognosis in esophageal squamous cell carcinoma
verfasst von: Asuka Murata
Yoshifumi Baba
Masayuki Watanabe
Hironobu Shigaki
Keisuke Miyake
Ryuichi Karashima
Yu Imamura
Satoshi Ida
Takatsugu Ishimoto
Shiro Iwagami
Yasuo Sakamoto
Yuji Miyamoto
Naoya Yoshida
Hideo Baba
Publikationsdatum: 01.12.2013
Verlag: Springer US
Erschienen in: Medical Oncology / Ausgabe 4/2013
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI: https://doi.org/10.1007/s12032-013-0728-z

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

p53 immunohistochemical expression and patient prognosis in esophageal squamous cell carcinoma

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2013

Long-term outcomes after curative resection for patients with macroscopically solitary hepatocellular carcinoma without macrovascular invasion and an analysis of prognostic factors

Serum C-reactive protein: a prognostic factor in metastatic urothelial cancer of the bladder

The importance of negative predictive value (NPV) of vulnerable elderly survey (VES 13) as a pre-screening test in older patients with cancer

Distribution of plasma fatty acids is associated with response to chemotherapy in non-Hodgkin’s lymphoma patients

S-1 plus CIK as second-line treatment for advanced pancreatic cancer

Peripheral CD45RO, PD-1, and TLR4 expression in metastatic colorectal cancer patients treated with bevacizumab, fluorouracil, and irinotecan (FOLFIRI-B)

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie